Aurobindo Pharma Limited (BOM:524804)
1,579.35
+3.90 (0.25%)
At close: Jul 31, 2026
Aurobindo Pharma Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Aurobindo Pharma stock has a consensus rating of "Buy" and an average price target of ₹1,571. The average 1-year stock price forecast is 0.54% lower than the current stock price, while the lowest is ₹1,185 (-24.97%) and the highest is ₹1,810 (+14.60%).
Price Target: ₹1,571 (-0.54%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aurobindo Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 14 | 15 | 13 | 13 | 13 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 1 | 1 | 5 | 5 | 5 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 2 | 2 | 2 | 2 | 2 |
| Total | 26 | 25 | 26 | 28 | 28 | 28 |
Financial Forecast
Revenue This Year
395.05B
from 336.53B
Increased by 17.39%
Revenue Next Year
436.11B
from 395.05B
Increased by 10.39%
EPS This Year
77.60
from 61.11
Increased by 26.98%
EPS Next Year
90.36
from 77.60
Increased by 16.44%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.